HCV dispute blamed for Murex' loss
This article was originally published in Clinica
Executive Summary
Murex has reported a net loss of $2.1 million in the third quarter ended September 30th, 1995, compared with a net income of $1.5 million in the same period last year. The Canadian company blames the continuing HCV patent dispute with Chiron. Because of the litigation, Murex has moved its HCV production site twice - to Italy and more recently to Morocco. Problems associated with this final move resulted in a $1.1 million loss in HCV sales, says Murex.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.